PLYMOUTH MEETING, PA — INOVIO (Nasdaq: INO) said it will present research on its DNA-based therapies at two upcoming scientific conferences in Europe and the United States.
The biotechnology company said it will participate in the Eurogin HPV Conference in Vienna on March 19 and the World Vaccine Congress in Washington, D.C., on March 30.
At the Eurogin HPV Conference, INOVIO will present data on INO-3107, a DNA immunotherapy targeting recurrent respiratory papillomatosis caused by HPV types 6 and 11.
The company said the presentation will focus on long-term reductions in the need for surgical interventions.
At the World Vaccine Congress, INOVIO said it will present data on its DNA-encoded monoclonal antibody technology, which is designed to enable in vivo production of antibodies targeting infectious diseases, including COVID-19.
The company said abstracts from both presentations will be made available on its website following the events.
INOVIO develops DNA-based medicines aimed at treating HPV-related diseases, cancer, and infectious diseases.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.